Who
Anthony G. Quinn
Director
Company insider
Files Form 4 as: Director, Generation Bio Co; President & CEO, Spyre Therapeutics; Director, Kaleido Biosciences; EVP, CMO, & Head of R&D, Synageva Biopharma.
In numbers
- Trades disclosed
- 170
- Buys
- 29
- Sells
- 14
- Bought
- $2.5M
- Sold
- $10.7M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 20 Dec 2011
- Last trade
- 9 Feb 2026
- Last filed
- 9 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio CoBiotechnology | SEC FORM 4 Code U | —29,928 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio CoBiotechnology | SEC FORM 4 Code U | —7,283 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —3,000 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —3,000 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —5,200 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —1,500 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —1,920 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —2,500 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —6,000 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —5,200 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —1,500 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —1,920 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —2,500 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —6,000 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Co | SEC FORM 4 Code U | —29,928 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Co | SEC FORM 4 Code U | —7,283 | filing |
| 4 Jun 2025filed 6 Jun 2025 | Generation Bio Cooption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 13 Jan 2025filed 14 Jan 2025 | Generation Bio Co | SEC FORM 4 Bought | $82K85,000 at $0.97 | filing |
| 10 Jan 2025filed 14 Jan 2025 | Generation Bio Co | SEC FORM 4 Bought | $121K125,791 at $0.96 | filing |
| 6 Jun 2024filed 10 Jun 2024 | Generation Bio Cooption or derivative | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
News
Financial Review: Intellia Therapeutics (NASDAQ:NTLA) versus Spyre Therapeutics (NASDAQ:SYRE)SYRE · themarketsdaily.com · 19 Oct 2026Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026SYRE · manilatimes.net · 18 Oct 2026
0 headlines in the last 90 days name Anthony G. Quinn; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.